New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules
- 214 Downloads
Purpose of Review
An update on new therapies currently approved or potentially useful in the future for the management of patients suffering moderate-to-severe atopic dermatitis.
New pathogenic mechanisms involved in atopic dermatitis have permitted to propose novel therapeutic approaches devised to control the inflammatory process observed in involved cutaneous tissues by neutralizing mediators, cytokines, and their receptors.
Recent research findings have disclosed important and previously unrecognized pathogenic mechanisms that have resulted in innovative targeted therapies, such as dupilumab, and potentially other biologicals and small molecules. Further studies should permit the sub-classification of patients according to the relevance of different mediators and inflammatory cells. It can be concluded that the treatment of atopic dermatitis has entered into the era of personalized/precision medicine.
KeywordsAtopic dermatitis Biologicals Dupilumab Eczema Small molecules Treatment
Investigator Global Assessment
Eczema Area and Severity Index
Thymus stromal lymphopoietin
Innate lymphoid cell
Scoring of Atopic Dermatitis
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Asher I, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood. ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368:733–43.CrossRefGoogle Scholar
- 5.• Eichenfeld LF, Ahluwalia J, Waldman A, Borok J, Udkoff JP, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139:S49–57. A comparative review of the management of AD in different world settings.CrossRefGoogle Scholar
- 6.•• Bieber T, D’Erme AM J, Akdis CA, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139:S58–64. An important proposal to classify AD into subtypes that would give orientation on best personalized approaches to the treatment.CrossRefGoogle Scholar
- 15.• Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77:623–33. An overview of the indications to use immune modulators and biologics in severe AD.CrossRefGoogle Scholar
- 16.Taleb A, Seneschal J, Mossalayi MD. Biologics in atopic dermatitis. J Dutch Dermatol Ges. 2012;10:174–8.Google Scholar
- 28.Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78:863–871.e11.CrossRefGoogle Scholar
- 29.Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2018. https://doi.org/10.1016/j.jaci.2018.05.029.
- 34.Thaci D, Contanstin MM, Rojkovich B, Timmis H, Klöpfer P, et al. MOR106, anti-IL-17C mAb, a potential new approach for treatment of moderate-to-severe atopic dermatitis. Phase 1 study. In Proceedings of the American Academy of Dermatology Annual Meeting, Orlando, FL, USA, 3–7 March 2017.Google Scholar
- 48.Simpson EL, Parnes JR, She D, Crouch S, Rees W, Mo M, et al. Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J Am Acad Dermatol. 2018. https://doi.org/10.1016/j.jaad.2018.11.059.
- 49.Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494–503.e6.CrossRefGoogle Scholar